Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes
04/04/2024
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Receives Reimbursement for Bladder EpiCheck® in the Netherlands
06/11/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Bladder EpiCheck® Now Available in France via the Association Francaise d'Urologie (AFU) Registry for Surveillance of Recurrence of Bladder Cancer
23/10/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Advances Early Lung Cancer Detection Program with Promising Performance Data and Appointment of Chief Scientific Officer
11/10/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
Nucleix Announces Upcoming Presentation of Performance Data from Sightline Study of Lung EpiCheck® at the American College of Chest Physicians (CHEST) 2023 Annual Meeting
02/10/2023
SAN DIEGO & REHOVOT, Israel--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced...
STAY UPDATED ON THE LATEST NEWS FROM NUCLEIX!
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.